Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 13/20 | 0.56 |
| ▸ | OGFRL1 | Q5TC84 | 11/20 | 0.56 |
| ▸ | OPRL1 | P41146 | 5/20 | 0.55 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.55 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.55 |
| ▸ | CFTR | P13569 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Citric Acid SCHEMBL2002776 | 0.91 | OPRM1 (0.48) | OPRM1OGFRL1OPRL1OPRD1OPRK1 | |
| SCHEMBL3563996 | 0.87 | OPRM1 (0.50) | OPRM1OGFRL1OPRL1OPRD1OPRK1 | |
| SCHEMBL3561227 | 0.82 | OPRM1 (0.58) | OPRM1OGFRL1OPRL1OPRD1OPRK1 | |
| SCHEMBL1702300 | 0.78 | OPRM1 (0.64) | OPRM1OGFRL1OPRL1OPRD1OPRK1 | |
| SCHEMBL14106671 | 0.76 | OPRM1 (0.50) | OPRM1OGFRL1OPRL1OPRD1OPRK1 | |
| SCHEMBL3578406 | 0.73 | OPRM1 (0.61) | OPRM1OGFRL1OPRL1OPRD1OPRK1 | |
| Lexanopadol SCHEMBL29930643 | 0.73 | OPRM1 (1.00) | OPRM1OGFRL1OPRL1OPRD1OPRK1 | |
| Lexanopadol SCHEMBL566559 | 0.73 | OPRM1 (1.00) | OPRM1OGFRL1OPRL1OPRD1OPRK1 | |
| Lexanopadol SCHEMBL381022 | 0.73 | OPRM1 (1.00) | OPRM1OGFRL1OPRL1OPRD1OPRK1 | |
| Lexanopadol SCHEMBL566686 | 0.73 | OPRM1 (1.00) | OPRM1OGFRL1OPRL1OPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2121691-B1 | SPIROCYCLIC CYCLOHEXANE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2012-04-18 | — | — | EP | disclosed |
| US-7960404-B2 | Spirocyclic cyclohexane compounds | GRUENENTHAL GMBH (DE) | 2011-06-14 | — | — | US | disclosed |
| US-20100048553-A1 | Spirocyclic Cyclohexane Compounds | GRUENENTHAL GMBH (DE) | 2010-02-25 | — | — | US | disclosed |
| EP-2121691-A1 | SPIROCYCLIC CYCLOHEXANE DERIVATIVES | Grünenthal GmbH (DE) | 2009-11-25 | — | — | EP | disclosed |
| WO-2008101660-A1 | SPIROCYCLIC CYCLOHEXANE DERIVATIVES | Grünenthal GmbH (DE) | 2008-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048553-A1 | Spirocyclic Cyclohexane Compounds | PKD2, PKD1, RYR1 | OPRM1 65/4885OGFRL1 672/4885OPRL1 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.